Baker JF, et al. - Experts presented the impact of disease-modifying therapies for rheumatoid arthritis (RA) on systolic and diastolic blood pressure (SBP, DBP) over 6 months and incident hypertension over 3 years in a large administrative database. The administrative Veterans Affairs databases were used to define unique dispensing episodes of methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, tumour necrosis factor inhibitors, and prednisone among patients with RA. Findings suggested that treatment of RA, particularly with methotrexate or hydroxychloroquine, improved the blood pressure. In contrast, there was an association of Leflunomide use with increases in blood pressure (BP) and a greater risk of incident hypertension.